Established in 2018, Quoin Pharmaceuticals Ltd. (QNRX) is a burgeoning company with a focus on advancements in pharmaceutical sciences. The company is incorporated in the United Kingdom and operates with an ambitious vision of addressing some of the most critical health issues that presently challenge global healthcare systems.
Quoin Pharmaceuticals devotes its resources to make distinctive products that are designed to improve the quality of life for patients worldwide. Their pharmaceutical development program is targeted at conditions that affect large patient populations such as military-related PTSD, migraines, and acute and chronic pain. Their initiatives are seen as a unique approach to the global health landscape, providing reliable and simplified solutions to the challenges that currently exist in the global pharmaceutical industry.
Their lead product, a non-addictive analgesic for relief from acute pain named QRX001, is a testament to the company's innovative approach. This drug is being designed to be an alternative to addictive opioids, which currently dominate the pain management market. This addresses a significant need, as opioid addiction is a crisis that affects across the globe.
By employing transdermal technology for drug administration, Quoin Pharmaceuticals attempts to maximize the efficacy and benefits of their products while reducing potential risks and side effects that can accompany traditional methods of medication intake.
The company shows strong commitment to ethical drug development and market practices, following stringent regulatory compliances and guidelines in their research and business operations. With this, Quoin Pharmaceuticals Ltd. aims to maintain robust relationships with stakeholders, including patients, healthcare providers, and investors.
With its promising products in development, Quoin Pharmaceuticals is constantly striving to disrupt the current healthcare paradigm with its forward-thinking dedication to addressing unmet medical needs. Despite being a relatively new entrant in the healthcare industry, QNRX has already begun to demonstrate its potential to revolutionize the pharmaceutical sector with its unique and innovative approach to drug development and delivery. Quoin Pharmaceuticals is not just a business enterprise but a mission-driven organization intending to make a tangible and positive difference in the world of healthcare and beyond.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Quoin Pharmaceuticals announced that the FDA has granted Rare Pediatric Disease (RPD) Designation for its lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS). This is the second RPD designation for QRX003, and if a New Drug Application is approved, Quoin may receive a Priority Review Voucher. The company plans to initiate a Phase 2 clinical study for PSS in the second half of 2026, enrolling up to 12 pediatric and adult patients.
Quoin Pharmaceuticals has received a second rare paediatric disease designation from the FDA for its candidate QRX003, which is being developed to treat Peeling Skin Syndrome (PSS). This designation makes Quoin eligible for a priority review voucher if QRX003 is approved, allowing them to expedite FDA review for another product or sell the voucher. The drug candidate, also designated for Netherton Syndrome, is preparing for a Phase II clinical study for PSS in the US and Europe.